<DOC>
	<DOCNO>NCT02546284</DOCNO>
	<brief_summary>This multicenter , open-label , repeat-dose , Phase 1 Dose Escalation Study evaluate safety , pharmacokinetics , clinical activity .</brief_summary>
	<brief_title>Study Lenzilumab ( KB003 ) Previously Treated Patients With Chronic Myelomonocytic Leukemia ( CMML )</brief_title>
	<detailed_description>The purpose study examine safety determine recommend Phase 2 dose lenzilumab ( KB003 ) administer subject previously treat CMML meet entry criterion . Study begin enrollment July 2016 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<criteria>Confirmed diagnosis CMML CMML refractory , progress follow treatment hypomethylating agent standard care treatment Eastern Cooperative Oncology Group ( ECOG ) score â‰¤ 2 Able provide bone marrow biopsy sample Acceptable laboratory result Leukemia CMML Recent chemotherapy radiation therapy ( within 14 day first dose lenzilumab ) Concurrent use human granulocytemacrophage colonystimulating factor Pregnant breastfeeding Know HIV virus infection History another malignancy within past 2 year ( skin cancer prostate cancer permit ) Significant intercurrent illness History current diagnosis Pulmonary Alveolar Proteinosis Hypoxemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CMML</keyword>
</DOC>